According to the International Association for the Study of Pain (IASP), pain is defined as an unpleasant experience (sensory and/or emotional) related to a potential or confirmed tissue damage or described in such terms.[1] Currently, the debate is ongoing whether or not this definition should be modified.[2][3][4] Nonetheless, the classification for pain management medications is stable; categories are nonopioid analgesic agents and opioid analgesic agents.
Nonopioid analgesic agents
Opioid agents
Opioids are a broad class of medications with structural resemblance to the natural plant alkaloids found in opium, which was originally derived from the resin of the opium poppy, Papaver somniferum.[11] They are recognized as the most effective and widely used drugs in treating severe pain.[12] Opioids have been among the most controversial analgesics, particularly because of their potential for addiction, tolerance, and side effects.[13] Although opioids have indications for acute and chronic pain treatment, the Center for Disease Control and Prevention's guidelines recommends that only if the expected benefits for both pain and function outweigh the risks, clinicians should prescribe opioids at the lowest effective dose and for the shortest expected duration to treat the pain severe enough to require opioids.[14][15][16][17]
Nonopioid analgesic agents
Opioid agents
The majority of the clinically relevant opioids act primarily at the “mu receptors” and thus are considered “mu agonists.”[25] Nonetheless, opioids may also act on other receptors: kappa, delta, and sigma (all of them, including mu, are G protein-coupled receptors). Depending on which receptor is activated, different physiologic effects occur (i.e., spinal and supraspinal analgesia). Opioids exert their effects at both presynaptic and postsynaptic neurons. Presynaptically, opioids block calcium channels on nociceptive afferent nerves, thus inhibiting the release of neurotransmitters such as substance P and glutamate. Postsynaptically, opioids enhance the activity of potassium channels, thus hyperpolarizing cell membranes and increasing the required action potential to generate nociceptive neurotransmission.[12][17]
Nonopioid analgesic agents
Opioid agents
Opioids are available in diverse dosage forms to use for several routes of administration: oral, transdermal, intramuscular, intravenous, subcutaneous infusion, rectal, epidural, intrathecal, intranasal, and transmucosal.[17][30] The rationale for each route of administration, dosage range, and the dosage form is dependent on a number of factors. For more detailed information, please review the American Pain Society guidelines.
Nonopioid analgesic agents
If administered intravenously, adverse effects include nausea, vomiting, pruritus, constipation, and abdominal pain.[6] For pediatric patients, regardless of the route of administration, the most common adverse reactions are nausea, vomiting, agitation, constipation, pruritus, and atelectasis.
For a complete list of adverse effects for a particular NSAID, please see the StatPearls article for the specific drug.
Opioid agents
Opioids produce a variety of different systemic adverse effects, including:
Nonopioid analgesic agents
Opioid agents
Nonopioid analgesic agents
Opioid agents
Clinicians should evaluate their patients on a periodical basis. Follow-ups should focus on the level of pain control and the physical examination (vital signs, signs of misuse, abuse, or addiction; respiratory and mental status; signs or symptoms of hypogonadism or hypoadrenalism).[17]
Nonopioid analgesic agents
Opioid agents
Opioid overdose may result in death due to severe respiratory depression. Physicians should suspect opioid toxicity in any patient presenting with altered mental status, bradypnea, and constricted pupils. Naloxone is indicated for patients with respiratory depression; it may be given intravenously, intramuscularly, or intranasally. Since naloxone is only active for 30 to 60 minutes, it must be administered through intravenous infusion in cases of a long-acting opioid overdose.[17][42]
Pain management requires a multidisciplinary healthcare team to address accurately and individually pain control for patients. Because adverse effects tend to occur at a much higher rate in patients with specific comorbidities, follow-ups must include a complete history and physical exam to alert for side effects or signs of addiction/misuse.
Patient education is crucial; providers need to pay close attention to the patient's symptoms and complaints to provide the best healthcare possible and avoid any adverse systemic effect. Several methods exist to detect any type of drug misuse appropriately. They include the following: state prescription drug monitoring programs, assessment surveys, adherence check-lists, motivational counseling, urine screening, and dosage forms verification. Through collaborative interprofessional teamwork, pain management can confer maximum benefit with minimal downside.
[1] | Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain. Supplement. 1986; [PubMed PMID: 3461421] |
[2] | Aydede M, Does the IASP definition of pain need updating? Pain reports. 2019 Sep-Oct; [PubMed PMID: 31875184] |
[3] | Alcock MM, Defining pain: past, present, and future. Pain. 2017 Apr; [PubMed PMID: 28301403] |
[4] | Cohen M,Quintner J,van Rysewyk S, Reconsidering the International Association for the Study of Pain definition of pain. Pain reports. 2018 Mar; [PubMed PMID: 29756084] |
[5] | Jóźwiak-Bebenista M,Nowak JZ, Paracetamol: mechanism of action, applications and safety concern. Acta poloniae pharmaceutica. 2014 Jan-Feb; [PubMed PMID: 24779190] |
[6] | Gerriets V,Anderson J,Nappe TM, Acetaminophen 2020 Jan; [PubMed PMID: 29493991] |
[7] | Finnerup NB, Nonnarcotic Methods of Pain Management. The New England journal of medicine. 2019 Jun 20; [PubMed PMID: 31216399] |
[8] | Ghlichloo I,Gerriets V, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 2020 Jan; [PubMed PMID: 31613522] |
[9] | Attal N, Pharmacological treatments of neuropathic pain: The latest recommendations. Revue neurologique. 2019 Jan - Feb; [PubMed PMID: 30318260] |
[10] | Finnerup NB,Attal N,Haroutounian S,McNicol E,Baron R,Dworkin RH,Gilron I,Haanpää M,Hansson P,Jensen TS,Kamerman PR,Lund K,Moore A,Raja SN,Rice AS,Rowbotham M,Sena E,Siddall P,Smith BH,Wallace M, Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet. Neurology. 2015 Feb; [PubMed PMID: 25575710] |
[11] | Opioids 2012; [PubMed PMID: 31643200] |
[12] | Zöllner C,Stein C, Opioids. Handbook of experimental pharmacology. 2007; [PubMed PMID: 17087119] |
[13] | Smith HS, Opioids and neuropathic pain. Pain physician. 2012 Jul; [PubMed PMID: 22786465] |
[14] | Guy GP Jr,Zhang K,Bohm MK,Losby J,Lewis B,Young R,Murphy LB,Dowell D, Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. MMWR. Morbidity and mortality weekly report. 2017 Jul 7; [PubMed PMID: 28683056] |
[15] | Chakote K,Guggenheimer J, Implications of use of opioid-containing analgesics for palliation of acute dental pain. Journal of opioid management. 2019 Jan/Feb; [PubMed PMID: 30855721] |
[16] | Aubrun F,Nouette-Gaulain K,Fletcher D,Belbachir A,Beloeil H,Carles M,Cuvillon P,Dadure C,Lebuffe G,Marret E,Martinez V,Olivier M,Sabourdin N,Zetlaoui P, Revision of expert panel's guidelines on postoperative pain management. Anaesthesia, critical care [PubMed PMID: 30822542] |
[17] | Cohen B,Ruth LJ,Preuss CV, Opioid Analgesics 2020 Jan; [PubMed PMID: 29083658] |
[18] | Chandrasekharan NV,Dai H,Roos KL,Evanson NK,Tomsik J,Elton TS,Simmons DL, COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America. 2002 Oct 15; [PubMed PMID: 12242329] |
[19] | Botting R,Ayoub SS, COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins, leukotrienes, and essential fatty acids. 2005 Feb; [PubMed PMID: 15626590] |
[20] | Brooks PM,Day RO, Nonsteroidal antiinflammatory drugs--differences and similarities. The New England journal of medicine. 1991 Jun 13; [PubMed PMID: 2034249] |
[21] | Munir MA,Enany N,Zhang JM, Nonopioid analgesics. The Medical clinics of North America. 2007 Jan; [PubMed PMID: 17164106] |
[22] | Scarborough BM,Smith CB, Optimal pain management for patients with cancer in the modern era. CA: a cancer journal for clinicians. 2018 May; [PubMed PMID: 29603142] |
[23] | Colloca L,Ludman T,Bouhassira D,Baron R,Dickenson AH,Yarnitsky D,Freeman R,Truini A,Attal N,Finnerup NB,Eccleston C,Kalso E,Bennett DL,Dworkin RH,Raja SN, Neuropathic pain. Nature reviews. Disease primers. 2017 Feb 16; [PubMed PMID: 28205574] |
[24] | Beecham GB,Bansal P,Nessel TA,Goyal A, Lidocaine 2020 Jan; [PubMed PMID: 30969703] |
[25] | Trescot AM,Datta S,Lee M,Hansen H, Opioid pharmacology. Pain physician. 2008 Mar; [PubMed PMID: 18443637] |
[26] | Agrawal S,Khazaeni B, Acetaminophen Toxicity 2020 Jan; [PubMed PMID: 28722946] |
[27] | McCrae JC,Morrison EE,MacIntyre IM,Dear JW,Webb DJ, Long-term adverse effects of paracetamol - a review. British journal of clinical pharmacology. 2018 Oct; [PubMed PMID: 29863746] |
[28] | Wright ME,Rizzolo D, An update on the pharmacologic management and treatment of neuropathic pain. JAAPA : official journal of the American Academy of Physician Assistants. 2017 Mar; [PubMed PMID: 28151738] |
[29] | Kukkar A,Bali A,Singh N,Jaggi AS, Implications and mechanism of action of gabapentin in neuropathic pain. Archives of pharmacal research. 2013 Mar; [PubMed PMID: 23435945] |
[30] | Inturrisi CE, Clinical pharmacology of opioids for pain. The Clinical journal of pain. 2002 Jul-Aug; [PubMed PMID: 12479250] |
[31] | Yasaei R,Katta S,Saadabadi A, Gabapentin 2020 Jan; [PubMed PMID: 29630280] |
[32] | Hayward KL,Powell EE,Irvine KM,Martin JH, Can paracetamol (acetaminophen) be administered to patients with liver impairment? British journal of clinical pharmacology. 2016 Feb; [PubMed PMID: 26460177] |
[33] | Bertolini A,Ferrari A,Ottani A,Guerzoni S,Tacchi R,Leone S, Paracetamol: new vistas of an old drug. CNS drug reviews. 2006 Fall-Winter; [PubMed PMID: 17227290] |
[34] | Cross AL,Viswanath O,Sherman Al, Pregabalin 2020 Jan; [PubMed PMID: 29261857] |
[35] | Penna A,Buchanan N, Paracetamol poisoning in children and hepatotoxicity. British journal of clinical pharmacology. 1991 Aug; [PubMed PMID: 1931463] |
[36] | Wong A,Graudins A, Risk prediction of hepatotoxicity in paracetamol poisoning. Clinical toxicology (Philadelphia, Pa.). 2017 Sep; [PubMed PMID: 28447858] |
[37] | Yeates PJ,Thomas SH, Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. British journal of clinical pharmacology. 2000 Jan; [PubMed PMID: 10606832] |
[38] | Levy G,Houston JB, Effect of activated charcoal on acetaminophen absorption. Pediatrics. 1976 Sep; [PubMed PMID: 958771] |
[39] | Chiew AL,Gluud C,Brok J,Buckley NA, Interventions for paracetamol (acetaminophen) overdose. The Cochrane database of systematic reviews. 2018 Feb 23; [PubMed PMID: 29473717] |
[40] | Hunter LJ,Wood DM,Dargan PI, The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open access emergency medicine : OAEM. 2011; [PubMed PMID: 27147851] |
[41] | Dhaliwal JS,Molla M, Duloxetine 2020 Jan; [PubMed PMID: 31747213] |
[42] | Oelhaf RC,Azadfard M, Opioid Toxicity 2020 Jan; [PubMed PMID: 28613731] |